MannKind receives Breakthrough T1D grant for pediatric Afrezza trial
Go back to MannKind receives Breakthrough T1D grant for pediatric Afrezza trial| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.54 -0.04 (1.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.58 | 52 Week High | $2.51 | |||
| Open | $3.59 | 52 Week Low | $0.41 | |||
| Day High | $3.62 | P/E | N/A | |||
| Day Low | $3.50 | EPS | $-0.64 | |||
| Volume | 5,512,814 | |||||
